

\$2.6m R&D refund received

Genetic Signatures Limited (ASX: GSS, “**Genetic Signatures**” or the “**Company**”) is pleased to announce that it has received a refund from the Australian Tax Office under its Research and Development (“**R&D**”) tax incentive program of \$2,574,928.

The R&D tax incentive is an Australian Government program under which companies receive cash refunds for eligible expenditure on R&D. The program encourages companies like Genetic Signatures to continue R&D activities in Australia that result in world-class technology with the potential to improve health outcomes and save lives.

Commenting on the refund, Genetic Signatures’ CEO Dr John Melki said: “The R&D tax incentive program is an important driver of innovation and we are pleased that it has assisted in the development of our 3base™ technology into a broad product pipeline in various stages of commercialisation.”

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base™**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures’ proprietary MDx **3base™** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki
Chief Executive Officer
john@geneticsignatures.com
T: +61 (0)2 9870 7580